However, it was the identification of GFRAL, a transmembrane receptor localised to the hindbrain, as the putative target for GDF15 and mediator of its weight lowering effects in rodents that framed GDF15 as a potential anti-obesity therapy [13–15]. This evidence concerns the gene NRP1 and obesity due to melanocortin 4 receptor deficiency.